Market Research Logo

Global Endometriosis Drugs Market 2016-2020

Global Endometriosis Drugs Market 2016-2020

About the Endometriosis Market

Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.

The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.

Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.

Technavio’s analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Endometriosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer
Other prominent vendors
  • Addex Therapeutics
  • Astellas Pharma
  • Debiopharm
  • ElexoPharm
  • Endoceutics
  • Euroscreen
  • Forendo Pharma
  • Isifer
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • ObsEva
  • Orphagen Pharmaceuticals
  • Philogen
  • PregLem
  • Repros Therapeutics
  • Roivant Sciences
  • SK Chemicals
  • Speciality European Pharma
  • SYNG Pharmaceuticals
  • Takeda
  • United Pharmaceuticals
  • ValiPharma
Market driver
  • Increased adoption of OCPs
  • For a full, detailed list, view our report
Market challenge
  • Surgeries as primary treatment option
  • For a full, detailed list, view our report
Market trend
  • Increased focus on intrauterine devices (IUDs)
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Endometriosis Market 2016-2020

Technavio recognizes the following companies as the key players in the global endometriosis market: AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer.

Other Prominent Vendors in the market are: Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, and ValiPharma.

Commenting on the report, an analyst from Technavio’s team said: “A trend boosting market growth is the increased focus on IUDs. Current treatment for endometriosis includes the use of GnRH agonists and oral contraceptives along with the use of surgeries. However, all these therapies are associated with many unwanted side effects due to hormonal changes in the body along with the early recurrence of the disease. Hence, the need for an effective replacement for these conventional therapies has led to the development of IUDs. Though IUDs were initially developed for effective birth control, their use has been extended to treat endometriosis. Levonorgestrel intrauterine system (LNG-IUS) devices such as Mirena and Skyla will release progestogen into the body through the IUD at low concentration for an extended period.”

According to the report, a key growth driver is the increased adoption of OCPs. OCPs also referred to as hormonal pills contain the female hormones, estrogen and progestin similar to that produced by the ovaries. Some of the pills may contain only progestin. Apart from being used as contraceptives, these hormone pills are found to be effective in treating endometriosis. They do not cure endometriosis but are helpful in controlling the pain and preventing the condition from worsening. These medicines are also found to lower the chances of getting endometrial and ovarian cancer, ovarian cysts, certain breast lumps, and also protects the individual from osteoporosis.

Further, the report states that one challenge that could hamper market growth is surgery as the primary treatment option.

Companies Mentioned

AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, ValiPharma.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Endometriosis: An overview
  • Pipeline analysis
    • Table Pipeline portfolio: Global endometriosis drugs market
    • Table Segmentation of pipeline molecules in different stages of development
    • Pipeline molecules based on their mechanism
      • Table Segmentation of pipeline molecules based on their mechanism of action
      • Table Impact of GnRH antagonists on global endometriosis market
      • Table Competitive assessment of marketed and late-stage pipeline molecules
  • Key buying criteria for endometriosis drugs
    • Table Key buying criteria for endometriosis drugs
  • Market landscape
    • Market overview
      • Table Global endometriosis market snapshot: Developed and emerging markets 2015
      • Table Global endometriosis drugs market 2015-2020 ($ billions)
      • Table Opportunity analysis: Global endometriosis drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of therapy
    • Table Segmentation of global endometriosis drugs market by type of therapy
    • Table Global endometriosis market segmentation by type of therapy 2015
    • Hormone therapy
    • Market size and forecast
      • Table Hormone therapies market for endometriosis 2015-2020 ($ billions)
    • Pain medications
    • Market size and forecast
      • Table Pain medications market for endometriosis 2015-2020 ($ millions)
      • Table Global endometriosis market by type of therapy 2015-2020
  • Market segmentation by ROA
    • Oral
    • Parenteral
    • Intrauterine systems
    • Nasal spray
  • Geographical segmentation
    • Global endometriosis drugs market by geography 2015-2020
      • Table Global endometriosis drugs market by geography 2015-2020
      • Table Segmentation of global endometriosis drugs market by geography 2015 and 2020
      • Table Segmentation of global endometriosis drugs market by geography 2015-2020 ($millions)
      • Table Global endometriosis market by geography 2015-2020
    • Endometriosis drugs market in Americas
      • Table Endometriosis drugs market in Americas 2015-2020 ($ millions)
    • Endometriosis drugs market in EMEA
      • Table Endometriosis prevalence in EMEA
      • Table Endometriosis drugs market in EMEA 2015-2020 ($ millions)
    • Endometriosis drugs market in APAC
      • Table Endometriosis drugs market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Recurrence of endometriosis
    • Increased adoption on OCPs
    • Ineffective existing therapies leading to high unmet need
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Poor compliance rates leading to high dropouts
    • Surgeries as primary treatment option
    • Unavailability of proper diagnostic tools
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Replacement of GnRH agonists by GnRH antagonists
    • Increased focus on IUDs
    • Development of novel targets for treatment
  • Vendor landscape
    • Competitive scenario
      • Table Market share of top vendors in global endometriosis drugs market 2015
      • Table Geographical presence of major vendors in global endometriosis market
      • Table Competitive scenario of vendors in global endometriosis market 2015-2020
    • Key news
    • Major upcoming vendors
      • Table Major upcoming vendors in global endometriosis market
  • Key vendor analysis
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
      • Table AbbVie: Geographical segmentation of Lupron by revenue 2015
      • Table AbbVie: Metrics analysis
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
      • Table AstraZeneca: Geographic segmentation of Zoladex 2015
      • Table AstraZeneca: Metrics analysis
    • Bayer HealthCare
      • Table Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions)
      • Table Bayer HealthCare: Metrics analysis
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions)
      • Table Pfizer: Metrics analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report